OC
PTLA

Oppenheimer & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Oppenheimer & Co’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-119,600
Closed -$853K – 1334
2020
Q1 		$853K Buy
119,600
+106,900
+842% +$1.33M 0.03% 577
2019
Q4 		$303K Sell
12,700
-10,216
-45% -$282K 0.01% 1019
2019
Q3 		$614K Buy
22,916
+393
+2% +$11K 0.02% 727
2019
Q2 		$611K Buy
22,523
+318
+1% +$9.97K 0.02% 740
2019
Q1 		$771K Sell
22,205
-2,551
-10% -$73.6K 0.02% 663
2018
Q4 		$483K Sell
24,756
-36,434
-60% -$749K 0.02% 742
2018
Q3 		$1.63M Buy
61,190
+47,594
+350% +$1.55M 0.04% 455
2018
Q2 		$514K Sell
13,596
-8,003
-37% -$306K 0.01% 850
2018
Q1 		$705K Buy
21,599
+16,354
+312% +$718K 0.02% 732
2017
Q4 		$256K Buy
+5,245
New +$265K 0.01% 1122

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Oppenheimer & Co's PTLA Position: Q2 2020 in Review

Oppenheimer & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 119,600 shares — an estimated $853K sold.

Oppenheimer & Co first reported a position in PTLA in Q4 2017 and held it in 10 quarters. The position peaked at $1.63M in Q3 2018. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Oppenheimer & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 119,600 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $853K.
  • Oppenheimer & Co first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 10 quarters.
  • Oppenheimer & Co's Portola Pharmaceuticals, Inc. position peaked at $1.63M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.